Jiangxi Rimag Group Acquires Majority Stake in Gaomai Health for RMB 54 Million

Reuters
22 Jun
Jiangxi Rimag Group Acquires Majority Stake in Gaomai Health for RMB 54 Million

Jiangxi Rimag Group Co., Ltd. has announced its acquisition of a majority stake in Guangzhou Gaomai Health Technology Co., Ltd. The transaction, involving Jiangxi Ganjiang New Area Rimag Health Management Limited, a wholly-owned subsidiary of Jiangxi Rimag Group, will see the purchase of 30.0%, 20.0%, and 20.0% equity interests from Guangdong Gaoshang Health Technology Group Co., Ltd., Xiamen Gaoshang Medical Imaging Diagnostic Center Co., Ltd., and Hefei Gaoshang Medical Imaging Diagnostic Center Co., Ltd., respectively. The total consideration for the acquisition is RMB54,000,000. Following the completion of this deal, Jiangxi Rimag will hold a 70.0% equity interest in Gaomai Health, making it a subsidiary of Jiangxi Rimag Group, with its financial results to be consolidated into the group's financial statements.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jiangxi Rimag Group Co. Ltd. published the original content used to generate this news brief on June 22, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10